Decision-making in lung cancer

Tumors of the Chest: Biology, Diagnosis and Management

Volumn , Issue , 2006, Pages 661-677

  Delaney, Geoff P ^a   French, Bruce G ^a  

^a LIVERPOOL HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892372605     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-31040-1_57     Document Type: Chapter

References (129)

1. Kravitz RL, Melnikow J. Engaging patients in the medical decision making. The end is worthwhile but the means need to be more practical. BMJ 2001;323:584.
2. Richardson GE, Thursfield VJ, Giles GG for the Anti-Cancer Council of Victoria Lung Cancer Study Group. Reported management of lung cancer in Victoria in 1993: comparison with best practice. Med J Aust 2000;172:321.
3. Kesson E, Bucknall CE, McAlpine LG, et al. Lung cancer: management and outcome in Glasgow, 1991-1992. Br J Cancer 1998;78:1391.
4. Gregor A, Thomson CS, Brewster DH, Stroner PL, Davidson J, Fergusson RJ, Milroy R on behalf of the Scottish Cancer Trials Lung Group and the Scottish Cancer Therapy Network. Management and survival of patients with lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax 2001;56:212.
5. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 1999;86:1867.
6. Vinod SK, Delaney GP, Bauman AE, Barton MB. Lung cancer patterns of care in south western Sydney, Australia. Thorax 2003;58:690.
7. Mahmud SM, Reilly M, Comber H. Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study. Lung Cancer 2003;41:57.
8. Vinod SK, Hui AC, Esmaili N, Hensley MJ, Barton MB. Comparison of patterns of care in lung cancer in three area health services in New South Wales, Australia. Intern Med/2004;34:677.
9. Raby B, Pater J, Mackillop W. Does knowledge guide practice? Another look at the management of non-small cell lung cancer. J Clin Oncol 1995;13:1904.
10. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002;20:1786.
11. Mackillop WJ, Dixon P, Zhou Y, et al. Variations in the management of non-small cell lung cancer in Ontario. Radiother Oncol 1994;32:106.
12. Schroen AT, Detterbeck FC, Crawford R, Rivera P, Socinski MA. Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer. Chest 2000;118:129.
13. Jennens RB, de Boer R, Irving L, DL Ball, Rosenthal MA. Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer. Chest 2004;126:1985.
14. Palmer MJ, O'Sullivan B, Steele R, Mackillop WJ. Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study. Radiother Oncol 1990;19:17.
15. Greenberg ER, Chute CG, Stukel T, Baron JA, Freeman DH, Yates J, Korson R. Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. New Engl J Med 1988;318:612.
16. Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004;22:3261.
17. Ball DL, Irving LB. Are patients with lung cancer the poor relations in oncology? We must abandon the nihilistic attitude to management of lung cancer. Med J Aust 2000;172:310.
18. Perez EA. Perceptions of prognosis, treatment and treatment impact on prognosis in non-small cell lung cancer. Chest 1998;114:593.
19. Yung RC, Orens JB. Radicalism in therapy of lung cancer. Lancet 2001;357:1306.
20. Grosclaude P, Galat JP, Mace-Lesech J, Roumagnac-Macheleard M, Mercier M, Robillard J. Differences in treatment and survival rates of non-small cell lung cancer in three regions of France. Br J Cancer 1995;72:1278.
21. Janssen-Heijnen MLG, Gatta G, Forman D, Capocaccia R, Coeburgh JWWand the EUROCARE Working Group. Variation in survival of patients with lung cancer in Europe 1985-1989. Eur J Cancer 1998;34:2191.
22. Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, Weeks JC. Who gets chemotherapy for metastatic lung cancer? Chest 2000;117:1239.
23. Jong KE, Smith DP, Yu XQ, et al. Remoteness of residence and survival from cancer in New South Wales. Med J Aust 2004;180:618.
24. Laroche C, Wells F, Coulden R, et al. Improving surgical resection rates in lung cancer. Thorax 1998;53:445.
25. Priestman TJ, Bullimore JA, Godden TP, Deutsch GP. The Royal College of Radiologists' fractionation survey. Clin Oncol 1989;1:39.
26. Maher EJ. The influence of national attitudes on the use of radiotherapy in advanced and metastatic cancer, with particular reference to differences between the United Kingdom and the United States of America: implications for future studies. Int J Radiat Oncol Biol Rhys 1990;20:1369.
27. Timothy AR, Girling DJ, Saunders MI, Macbeth F, Hoskin PJ on behalf of the participants of the second Workshop on Palliative Radiotherapy and Symptom Control. Consensus statement. Radiotherapy for inoperable lung cancer. Clin Oncol 2001;13:86.
28. Choy H, Shyr Y, Cmelak AJ, Mohr PJ, Johnson DH. Patterns of practice survey for nonsmall cell lung carcinoma in the U. S. Cancer 2000;88:1336.
29. Sambrook RJ, Girling DJ. A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom. Br J Cancer 2001;84:1447.
30. Ayanian JZ, Chrischilles EA, Fletcher RH, et al. Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol 2004;22:2992.
31. Wang KP, Haponik EF, Britt EJ, Khouri N, Erozan Y Transbronchial needle aspiration of peripheral pulmonary nodules. Chest 1984;86:819.
32. Gould M, Maclean C, Kuschner W, Rydzak C, Owens D Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914.
33. Pieterman RM, von Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254.
34. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388.
35. Cheran SK, Herndon JE II, Patz EF Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer 2004;44:317.
36. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two, six and twelve minute walking tests in respiratory disease. BM] 1982;284:1607.
37. Bagg LR. The 12 minute walking distance: its use in the preoperative assessment of patients with bronchial carcinoma before lung resection. Respiration 1984;46:342.
38. Markos J, Mullan BP, Hillman DR, et al. Preoperative assessment as a predictor of mortality and morbidity after lung resection. Am Rev Respir Dis 1989;139:902.
39. Ferguson MK, Little L, Rizzo L, et al. Diffusing capacity predicts mortality after pulmonary resection. J Thome Cardiovase Surg 1988;86:894.
40. Larsen KR, Lund JO, Svendsen UG, Milman N, Petersen BN. Prediction of post-operative cardiopulmonary function using perfusion scintigraphy in patients with bronchogenic carcinoma. Clin Physiol 1997;17:257.
41. Cordiner A, De Carlo F, De Gennaro R, Pau F, Flore F. Prediction of postoperative pulmonary function following thoracic surgery for bronchial carcinoma. Angiology 1991;42:985.
42. Wernly JA, De Meester TR, Kirchner PT, Myerowitz PD, Oxford DE, Golomb HM. Clinical value of quantitative ventilation-perfusion lung scans in the surgical management of bronchogenic carcinoma. J Thome Cardiovase Surg 1980;80:535.
43. Walsh GL, Morice RC, Putnam JB, et al. Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption. Ann Thome Surg 1994;58:704.
44. Ribas J, Diaz O, Barbera JA, et al. Invasive exercise testing in the evaluation of patients at high risk for lung resection. Eur Respir] 1998;12:1429.
45. Villani F, De Maria P, Busia A. Exercise testing as a predictor of surgical risk after pneumonectomy for bronchogenic carcinoma. Respir Med 2003;97:1296.
46. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Rhys 1999;45:323.
47. Kwa SLS, Lebesque JV, Theuws JCM, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Rhys 1998;42:1.
48. Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 2001;51:650.
49. Tsujino K, Hirota S, Endo M, et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Onol Biol Phys 2003;55:110.
50. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase II randomized trial. J Natl Cane Inst 2003;95:362.
51. Scott C, Sause WT, Byhardt R, Marcial V, Pajak TF, Herskovic A, Cox JD. Recursive partitioning of 1, 592 patients on four Radiation Therapy Oncology Group studies in inoperable non-small cell lung cancer. Lung Cancer 1997;17(suppl 1):S59.
52. Wigren T, Kolari. A practical prognostic index for inoperable non-small cell lung cancer. Methods Inf Med 1994;33:397.
53. Wigren T. Confirmation of a prognostic index for inoperable non-small cell lung cancer. Radiother Oncol 1997;44:9.
54. Erkurt E, Tunali C, Erkisi. Primary therapeutic decision making in inoperable non-small cell lung cancer. Int J Radiat One Biol Phys 2000;46:439.
55. Damhuis RAM, Schutte PR. Resection rates and postoperative mortality in 7, 899 patients with lung cancer. Eur Respir J 1996;9:7.
56. Ishida T, Yokoyama H, Kaneko S, Sugio K, Sugimachi K. Long-term results of operation for non-small cell lung cancer in the elderly. Ann Thorae Surg 1990;50:919.
57. Sherman S, Duidot CE. The feasibility of thoracotomy for lung cancer in the elderly. JAMA 1987;258:30.
58. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oneol 2001;19:1064.
59. Gridelli C, Ardizzoni A, Le Chavalier T, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of a European Experts Panel. Ann Oneol 2004;15:419.
60. Begg CB, Cohen JL, Ellerton J. Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Caneer Clin Trials 1980;3:369.
61. Chen H, Cantor A, Meyer J, et al. Can older patients tolerate chemotherapy? A prospective pilot study. Caneer 2003;97:1107.
62. Shepherd FA, Amdemichael E, Evans WK, Chalvardjian P, Hogg-Johnson S, Coates R, Paul K. Treatment of small cell lung cancer in the elderly. J Am Geriatr Soe 1994;42:64.
63. Brown JS, Eraut D, Trask C, Davison AG. Age and the treatment of lung cancer. Thorax 1996;51:564.
64. Rose JH, O'Toole EE, Dawson NV, et al. Age differences in care practices and outcomes for hospitalized patients with cancer. J Am Geriatr Soe 2000;48:S25.
65. Delaney G, Barton M, Jacob S, Jalaludin B. A model for decision making for the use of radiotherapy in lung cancer. Laneet Oneol 2003;4:120.
66. Tyldesley S, Zhang-Salomans J, Groome P. Association between age and the utilization of radiotherapy in Ontario. Int J Radiat Biol Phys 2000;47:469.
67. Mackillop WJ, O'Sullivan B, Ward GK. Non-small lung cancer: how oncologists want to be treated. Int J Radiat Oneol Biol Phys 1987;13:929.
68. Harpole LH, Kelley MJ, Schreiber G, Toloza EM, Kolimaga J, McCrory DC. Assessment of the scope and quality of clinical practice guidelines in lung cancer. Chest 2003;123:7S.
69. Evans WK, Newman T, Graham I, Rusthoven JJ, Logan D, Shepherd FA, Chamberlain D. Lung cancer practice guidelines: lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group. J Clin Oneol 1997;15:3049.
70. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oneol Biol Phys 2001;50:287.
71. Browman GP. Improving clinical practice guidelines for the 21st century. Attitudinal barriers and not technology are the main challenges. Int J Techniques Assess Health Care. 2000;16:959.
72. McCusker J, Wax A, Bennett JM. Cancer patients accessions into clinical trials. A pilot investigation into some patient and physician determinants of entry. Am J Clin Oneol 1982;5:227.
73. Lescoe-Long M, Long MT. Defining the utility of clinically acceptable variations in evidence-based practice guidelines for evaluation of quality improvement activities. Evaluation Health Professions 1999;22:298.
74. Gunderson L. The effect of clinical practice guidelines on variations in care. Ann Intern Med 2000;133:317.
75. Ellrodt AG, Connor L, Riedinger M, Weingarten S. Measuring and improving physician compliance with clinical practice guidelines. A controlled intervention trial. Ann Intern Med 1995;122:277.
76. Long MJ. Clinical practice guidelines: when the tool becomes the rule. J Evaluation Clin Praet 2001;7:191.
77. Macbeth F. All evidence was considered when COIN guidelines were drawn up. BMJ 2000;320:1604.
78. O'Brien M, Cullen M. Guidelines must help bring us in line with European standards. BMJ 2000;320:1604.
79. Ardizonni A, Grossi F, Salvati F, Silvano G, Santi L. Common international guidelines must be developed. BMJ 2000;320:379.
80. Graham ID, Evans WK, Logan D, et al. Canadian oncologists and clinical practice guidelines: a national survey of attitudes and reported use. Oncology 2000;59:283.
81. Smith TJ, Hillner BE. Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oneol 2001;19:2886.
82. Gabel M, Hilton NE, Nathanson SD Multidisciplinary breast cancer clinics: do they work? Cancer 1997;79:2380.
83. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of vigorous evaluations. Laneet 1993;342:1317.
84. Olivotto IA, Bajdik CD, Plenderleith IH, et al. Adjuvant systemic therapy and survival after breast cancer. N Engl J Med 1994;330:805.
85. Tyldesley S, Boyd C, Schulze K, Walker H, Mackillop WJ. Estimating the need for radiotherapy for lung cancer: an evidence-based epidemiologic approach. Int J Radiat Oncol Biol Phys 2001;49:973.
86. Lenhard RE Jr, Waalkes TP, Herring D. Evaluation of the clinical management of cancer patients. A pilot study. JAMA 1983;250:3310.
87. Fergusson RJ, Gregor A, Dodds R, Kerr G. Management of ling cancer in South East Scotland. Thorax 1996;51:569.
88. Billing JS, Wells FC. Delays in the diagnosis and surgical treatment of lung cancer. Thorax 1996;51:903.
89. Alberts M, Bepler G, Hazelton T, Ruckdeschel JC, Williams JH Jr. Practice organization. Chest 2003;123:332S.
90. Jefford M, Tattersall MHN. Informing and involving cancer patients in their own care. Laneet Oneol 2002;3:629.
91. Mazur DJ, Hickam DH. Patients' and physicians' interpretations of graphic data displays. Med Decis Making 1993;13:59.
92. Jenkins V, Fallowfield L, Saul J. Information needs of patients with cancer: results from a large study in UK cancer centres. Br J Cancer 2001;84:48.
93. Degner LF, Kristjanson LJ, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA 1997;277:1485.
94. Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998;279:1709.
95. Smith TJ, Swisher K. Telling the truth about terminal cancer. JAMA 1998;279:1746.
96. Cassell EJ. The nature of suffering and the goals of medicine. N Engl J Med 1982;27(suppl 3):S110.
97. Lamont E, Christakis N. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med 2001;134:1196.
98. GIVIO (Interdisciplinary Group for Cancer Care Evaluation) Italy. What doctors tell patients with breast cancer about diagnosis and treatment: findings from a study in general hospitals. Br J Cancer 1986;54:319.
99. Gattellari M, Voigt KJ, Butow PN, Tattersall MH. When the treatment goal is not cure: are cancer patients equipped to make informed decisions? J Clin Oncol 2002;20:503.
100. Tattersall MH, Gatellari M, Voigt K, Butow PN. When the treatment goal is not cure: are patients informed adequately? Support Care Cancer 2002;10:314.
101. Hagerty RG, Butow PN, Ellis PA, et al. Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 2004;22:1721.
102. Schwartz I, Woloshin S, Black W, Welch H. The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 1997;127:966.
103. Lloyd A, Hayes P, Bell P, Naylor A. The role of risk and benefit perception in informed consent for surgery. Med Decis Making 2001;21:141.
104. Tattersall MH, Butow PN. Consultation audio tapes: an underused cancer patient information aid and clinical research tool. Lancet Oncol 2002;3:431.
105. Thomas R, Daly M, Perryman B, Stockton D. Forewarned is forearmed: benefits of preparatory information on video cassette for patients receiving chemotherapy or radiotherapy: a randomised trial. Eur J Cancer 2000;36:1536.
106. Fiset V, O'Connor AM, Evans W, et al. Development and evaluation of a decision aid for patients with stage IV non-small cell lung cancer. Health Expect 2000;3:125.
107. Charnock D, Shepperd S, Needham G, Gann R. DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. J Epidemiol Community Health 1999;53:105.
108. Brown RF, Butow PN, Boyer MJ, Tattersall MH. Promoting patient participation in the cancer consultation: evaluation of a prompt sheet and coaching in question-asking. Br J Cancer 1999;80:242.
109. Zhang AY, Siminoff LA. The role of the family in treatment decision making by patients with cancer. Oncol Nurs Forum 2003;30:1022.
110. Leighl NB, Butow PN, Tattersall MHN. Treatment decision aids in advanced cancer: when the goal is not cure and the answer is not clear. J Clin Oncol 2004;22:1759.
111. Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, Julian J, Dent S, Abu-Zahra H, Chouinard E, Tozer R, Pritchard K, Bodendorfer I. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph-node negative breast cancer. J Natl Cancer Inst 2003;95:581.
112. Whelan T, Levine M, Willan A, Gafni A, Sanders K, Mirsky D, Chambers S, O'Brien MA, Reid S, Dubois S. Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomised trial. JAMA 2004;292:435.
113. Ravdin PM, Siminoff L, Hewlett J, et al. Evaluation of impact of communication tool generated by the computer program Adjuvant! on patients with early breast cancer and their doctors (abstract 119). Proc Am Soc Clin Oncol 2001;20:31a.
114. De Laurentiis M, De Placido S, Bianco AP, Clark GM, Ravdin PM. A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients. Clin Cancer Res 1999;5:4133.
115. Torrance G, Thomas W, Sacket D A utility maximization model for the evaluation of health programs. Health Serv Res 1972;7:118.
116. Elwyn G, Edwards A, Eccles M, Rovner D. Decision analysis in patient care. Lancet 2001;358:571.
117. Dowie J, Wildman M. Choosing the surgical mortality threshold for high risk patients with stage la non-small cell lung cancer: insight from decision analysis. Thorax 2002;57:7.
118. Macbeth F. Decision analysis in NSCLC. Thorax 2002;57:919.
119. Treasure T. Whose lung is it anyway? Thorax 2002;57:3.
120. Brundage MD, Feldman-Stewart D, Cosby R, Gregg R, Dixon P, Youssef Y, Davies D, Mackillop WJ. Phase I study of a decision aid for patients with locally advanced nonsmall-cell lung cancer. J Clin Oncol 2001;19:1326.
121. Brundage MD, Davidson JR, Mackillop WJ, Feldman-Stewart D, Groome P. Using a treatment trade-off method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer. Med Decis Making 1998;18:256.
122. Griffin JP, Nelson JE, Koch KA, Niell HB, Ackerman TF, Thompson M, Cole FH Jr. End-of-life care in patients with lung cancer. Chest 2003;123:312S.
123. Silveira MJ, Di Piero A, Gerrity MS, Feudtner C. Patients' knowledge of options at the end of life: ignorance in the face of death. JAMA 2000;132:825.
124. Maguire P. Improving communication with cancer patients. Eur J Cancer 1999;35:1415.
125. Curtis JR, Wenrich MD, Carline JD, Shannon SE, Ambrozy DM, Ramsey PG. Patients' perspectives on physician skill in end-of-life care. Differences between patients with COPD, cancer and AIDS. Chest 2002;122:356.
126. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with endstage chronic obstructive pulmonary disease (COPD) ? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000;55:1000.
127. Girgis A, Sanson-Fisher RW Breaking bad news: consensus guidelines for medical practitioners. J Clin Oncol 1995;13:2499.
128. Speice J, Harkness J, Laneri R, et al. Involving family members in cancer care: focus group considerations of patients and oncological providers. Psychooncology 2000;9:101.
129. von Roenn JH, von Gunten CF. Setting goals to maintain hope. J Clin Oncol 2003;21:570.